Prophylaxis of heterotopic ossification after total hip arthroplasty: a prospective randomized study comparing indomethacin and meloxicam.

Abstract

We performed a randomized, prospective study on the prophylaxis of heterotopic ossification (HO) after total hip arthroplasty (THR), comparing indomethacin and the selective COX-2 inhibitor meloxicam. From the day after surgery, 272 patients were treated with 7.5 mg meloxicam, 15 mg meloxicam, or 2 x 50 mg indomethacin a day, for 14 days. After 6 months, radiographs of patients treated with 7.5 mg meloxicam showed that HO had occurred in one third. This treatment was therefore stopped after 26 patients have been assigned to this group. According to the intention-to-treat principle, patients given 15 mg meloxicam developed HO in 25% (20% Brooker grade I, 4% grade II and 1% grade III) and those given indomethacin in 10% (7% Brooker grade I, 1% grade II and 2% grade III), a statistically significant difference.

• Authors: Thomas Barthel, Bernd Baumann, Ulrich Nöth, Jochen Eulert
• Journal: Acta orthopaedica Scandinavica (Acta Orthop Scand) Vol. 73 Issue 6 Pg. 611-4 (Dec 2002) ISSN: 0001-6470 [Print] England
• PMID: 12553505 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Cyclooxygenase Inhibitors
• Thiazines
• Thiazoles
• Meloxicam
• Indomethacin

Topics

• Aged
• Anti-Inflammatory Agents, Non-Steroidal (therapeutic use)
• Arthroplasty, Replacement, Hip (adverse effects)
• Cyclooxygenase Inhibitors (therapeutic use)
• Female
• Humans
• Indomethacin (therapeutic use)
• Male
• Meloxicam
• Middle Aged
• Ossification, Heterotopic (diagnostic imaging, etiology, prevention & control)
• Postoperative Complications
• Prospective Studies
• Radiography
• Severity of Illness Index
• Thiazines (therapeutic use)
• Thiazoles (therapeutic use)